- Home
- Publications
- Publication Search
- Publication Details
Title
Shedding New Light
Authors
Keywords
-
Journal
PEDIATRIC CLINICS OF NORTH AMERICA
Volume 70, Issue 5, Pages 937-950
Publisher
Elsevier BV
Online
2023-09-12
DOI
10.1016/j.pcl.2023.05.007
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome
- (2022) Taizo A. Nakano et al. JOURNAL OF PEDIATRICS
- MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus
- (2022) Peter M K de Blank et al. NEURO-ONCOLOGY
- Succesful MEK-inhibition of severe hypertrophic cardiomyopathy in RIT1-related Noonan Syndrome
- (2022) Anne Leegaard et al. European Journal of Medical Genetics
- Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment
- (2022) Leah J. Kershner et al. JCI Insight
- Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial
- (2021) Michael J. Fisher et al. NATURE MEDICINE
- Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1)
- (2021) Michael J. Fisher et al. ACTA NEUROPATHOLOGICA
- FDA Approval Summary: Selumetinib for Plexiform Neurofibroma
- (2021) Denise Casey et al. CLINICAL CANCER RESEARCH
- NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
- (2021) Brian D. Weiss et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020
- (2021) Jace P. Landry et al. JAMA Network Open
- MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
- (2021) Anja Harder Biomarker Research
- Recurrent NF1 gene variants and their genotype/phenotype correlations in patients with Neurofibromatosis type I
- (2021) Matteo Riva et al. GENES CHROMOSOMES & CANCER
- Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
- (2021) Eric Legius et al. GENETICS IN MEDICINE
- Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1
- (2021) Karin S. Walsh et al. Neurology-Genetics
- Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants
- (2021) Hildegard Kehrer-Sawatzki et al. HUMAN GENETICS
- The structure of neurofibromin isoform 2 reveals different functional states
- (2021) Andreas Naschberger et al. NATURE
- The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1
- (2021) Christopher J. Lupton et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Implications of New Understandings of Gliomas in Children and Adults with NF1: Report of a Consensus Conference
- (2020) Roger J Packer et al. NEURO-ONCOLOGY
- Selumetinib in Children with Inoperable Plexiform Neurofibromas
- (2020) Andrea M. Gross et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
- (2020) Laura J. Klesse et al. ONCOLOGIST
- A molecular basis for neurofibroma-associated skeletal manifestations in NF1
- (2020) Yun Ma et al. GENETICS IN MEDICINE
- Modulation of spine fusion with BMP-2, MEK inhibitor (PD0325901), and zoledronic acid in a murine model of NF1 double inactivation
- (2020) Justin D. Bobyn et al. JOURNAL OF ORTHOPAEDIC SCIENCE
- Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR
- (2020) Wupeng Yan et al. Cell Reports
- Are Some Randomized Clinical Trials Impossible?
- (2020) Jonathan J. Rios et al. JOURNAL OF PEDIATRIC ORTHOPAEDICS
- Severe Lymphatic Disorder Resolved With MEK Inhibition in a Patient With Noonan Syndrome and SOS1 Mutation
- (2020) Yoav Dori et al. PEDIATRICS
- Pediatric malignancies in neurofibromatosis type 1: a population‐based cohort study
- (2019) Sirkku Peltonen et al. INTERNATIONAL JOURNAL OF CANCER
- Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition
- (2019) Gregor Andelfinger et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
- (2019) Jason Fangusaro et al. LANCET ONCOLOGY
- Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside
- (2019) Justin Korfhage et al. MOLECULAR CANCER RESEARCH
- The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin
- (2019) Frank L. Rice et al. PLoS One
- Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells
- (2018) Katarzyna J. Radomska et al. Cancer Discovery
- Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway
- (2018) Zhiguo Chen et al. Cancer Discovery
- Prevalence of neurofibromatosis type 1 in the Finnish population
- (2017) Roope A Kallionpää et al. GENETICS IN MEDICINE
- Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
- (2016) Eva Dombi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The genomic landscape of juvenile myelomonocytic leukemia
- (2015) Elliot Stieglitz et al. NATURE GENETICS
- Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1
- (2015) Edwin Jousma et al. PEDIATRIC BLOOD & CANCER
- Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions
- (2014) Katherine E Schwetye et al. Expert Review of Neurotherapeutics
- RAS diseases in children
- (2014) C. M. Niemeyer HAEMATOLOGICA
- Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
- (2014) B. C. Widemann et al. NEURO-ONCOLOGY
- NF1 Molecular Characterization and Neurofibromatosis Type I Genotype-Phenotype Correlation: The French Experience
- (2013) Audrey Sabbagh et al. HUMAN MUTATION
- Recommendations for imaging tumor response in neurofibromatosis clinical trials
- (2013) E. Dombi et al. NEUROLOGY
- Injury Signals Cooperate with Nf1 Loss to Relieve the Tumor-Suppressive Environment of Adult Peripheral Nerve
- (2013) Sara Ribeiro et al. Cell Reports
- Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition
- (2012) Carlos E. Prada et al. ACTA NEUROPATHOLOGICA
- Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma
- (2012) D. H. Gutmann et al. GENOME RESEARCH
- MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
- (2012) Walter J. Jessen et al. JOURNAL OF CLINICAL INVESTIGATION
- Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial
- (2012) Kent A Robertson et al. LANCET ONCOLOGY
- Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1
- (2012) M. Kolberg et al. NEURO-ONCOLOGY
- Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging
- (2011) Jianqiang Wu et al. PEDIATRIC BLOOD & CANCER
- A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice
- (2011) N. Lyubynska et al. Science Translational Medicine
- Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans
- (2010) Elisabeth A. Lasater et al. JOURNAL OF CLINICAL INVESTIGATION
- The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation
- (2009) William E Tidyman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Clinical and Mutational Spectrum of Neurofibromatosis Type 1–like Syndrome
- (2009) Ludwine Messiaen JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Plexiform and Dermal Neurofibromas and Pigmentation Are Caused by Nf1 Loss in Desert Hedgehog-Expressing Cells
- (2008) Jianqiang Wu et al. CANCER CELL
- The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders
- (2008) Yoko Aoki et al. HUMAN MUTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started